Hyloris Pharmaceuticals SA (HYL.BR)

12.00 +0.05 (+0.42%) At close: 05:35PM CEST

Hyloris Pharmaceuticals SA

Boulevard Patience et Beaujonc N°3/1
Liège 4000
Belgium
32 4 346 02 07
https://hyloris.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Stijn Van Rompay	Co-Founder, CEO & Director	N/A	N/A	1976
Mr. Thomas Jacobsen	Co-Founder, Chief Business Development Officer & Executive Director	N/A	N/A	1975
Mr. Jean-Luc Vandebroek	Chief Financial Officer	N/A	N/A	1973
Dr. Dietmar Aichhorn Ph.D.	Chief Operating Officer	N/A	N/A	N/A
Mr. Sven Watthy	Investor Relations Manager & Communications manager	N/A	N/A	1991
Mr. Koenraad Van Der Elst	Chief Legal Officer	N/A	N/A	1962

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health and other major therapeutic areas. It offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. The company provides Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative non-opioid pain management; Tranexamic acid RTU, an antifibrinolytic drug for the formation of blood clots; Miconazole/Domiphen Bromide, a topical synergistic combination treatment for Recurrent Vulvovaginal Candidiasis; AlenuraTM, a first-line drug treatment for acute pain in interstitial cystitis/bladder pain syndrome; and Plecoid Agent IV for the treatment of acute myeloid leukemia and small cell lung cancer. It also offers Atomoxetine, an oral liquid for the treatment of patients with attention deficit hyperactivity disorder; HY-029, a liquid formulation of an antiviral drug to treat viral infections; HY-083, a nasal spray for the treatment of idiopathic rhinitis; and HY-088, an oral liquid that treats hypophosphatemia. The company was incorporated in 2012 and is headquartered in Liège, Belgium.

Corporate governance

Hyloris Pharmaceuticals SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.